ArticleCost effectiveness and resource allocation : C/E2025

Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China.

Yueyang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.